Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics

Mortality remains alarmingly high for patients diagnosed with pancreatic ductal adenocarcinoma (PDAC), with 93% succumbing to the disease within five years. The vast majority of PDAC cases are driven by activating mutations in the proto-oncogene KRAS, which results in constitutive proliferation and...

Descripción completa

Detalles Bibliográficos
Autores principales: Smigiel, Jacob M., Parameswaran, Neetha, Jackson, Mark W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789364/
https://www.ncbi.nlm.nih.gov/pubmed/29320425
http://dx.doi.org/10.3390/cancers10010014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789364/
https://www.ncbi.nlm.nih.gov/pubmed/29320425
http://dx.doi.org/10.3390/cancers10010014

Ejemplares similares